Wellington Management Group
BTAI icon

Wellington Management Group’s BioXcel Therapeutics BTAI Stock Holding History

Wellington Management Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,310
Closed -$109K – 1899
2023
Q4 		$109K Hold
2,310
– – ﹤0.01% 1807
2023
Q3 		$93.5K Sell
2,310
-72,899
-97% -$7.37M ﹤0.01% 1793
2023
Q2 		$8.01M Sell
75,209
-8,204
-10% -$2.73M ﹤0.01% 1160
2023
Q1 		$24.9M Buy
+83,413
New +$35.6M ﹤0.01% 882
2022
Q3 		– Sell
-1,650
Closed -$349K – 2035
2022
Q2 		$349K Hold
1,650
– – ﹤0.01% 1922
2022
Q1 		$552K Buy
1,650
+110
+7% +$31.9K ﹤0.01% 1890
2021
Q4 		$501K Buy
+1,540
New +$661K ﹤0.01% 1980
2018
Q2 		– Sell
-708
Closed -$116K – 2236
2018
Q1 		$116K Buy
+708
New +$118K ﹤0.01% 2177

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wellington Management Group's BTAI Position: Q1 2024 in Review

Wellington Management Group sold out of BioXcel Therapeutics (BTAI) in Q1 2024, closing a stake of 2,310 shares — an estimated $109K sold.

Wellington Management Group first reported a position in BTAI in Q1 2018 and held it in 8 quarters. The position peaked at $24.9M in Q1 2023. 73 funds tracked by Wall St. Rank hold BTAI as of Q1 2024.

  • Wellington Management Group reported no remaining BioXcel Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wellington Management Group sold 2,310 BioXcel Therapeutics shares in Q1 2024, an estimated $109K.
  • Wellington Management Group first reported a position in BioXcel Therapeutics in Q1 2018 and held it in 8 quarters.
  • Wellington Management Group's BioXcel Therapeutics position peaked at $24.9M in Q1 2023.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2024.

Based on Wellington Management Group's 13F filing for Q1 2024, filed 15 May 2024.